Skip to content

Does Medicare cover Wegovy?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Medicare Part D doesn't cover Wegovy for weight loss, but there are two routes. Through the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027), eligible Part D enrollees pay $50 per month for the Wegovy pen or pill. According to CMS, Part D can also cover Wegovy to reduce cardiovascular risk in adults with established cardiovascular disease.

Source: Medicare GLP-1 Bridge

Key takeaways

  • Part D doesn't cover Wegovy for weight loss alone.
  • If you're an eligible Part D enrollee, the Medicare GLP-1 Bridge costs $50 per one-month supply, through December 31, 2027.
  • Part D can cover Wegovy to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.
  • If your Part D plan has paid for a GLP-1 in 2026, you can't use the Bridge.
  • The Wegovy savings card excludes government beneficiaries, so you can't use it with Medicare.

Whether Medicare pays for Wegovy comes down to the reason on the prescription. For weight loss alone, Part D (Medicare’s drug coverage) is barred by law, and the temporary Medicare GLP-1 Bridge is the route. For cardiovascular risk reduction, Part D can cover it. This page sorts out which route fits which situation. It sits under our Medicare and GLP-1 guide, and the medicine itself is covered on the Wegovy page.

The short version

  • Wegovy for weight management: not covered by Part D. Eligible Part D enrollees can get it through the Bridge for $50 per one-month supply until December 31, 2027.
  • Wegovy to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight: coverable by Part D, through your plan.
  • Wegovy for MASH, a liver condition: CMS lists noncirrhotic MASH with moderate to advanced liver scarring as an indication eligible for Part D coverage, and Wegovy injection’s label includes that use. This also goes through your plan.

Why Part D will not pay for Wegovy for weight loss

The Part D statute excludes “agents when used for anorexia, weight loss, or weight gain” from the definition of a covered Part D drug. CMS has applied that since Part D began, without separating people who have obesity from people who don’t. Under that policy, an anti-obesity medication is coverable only when it’s used for another medically accepted indication.

So the same pen can be covered for one patient and excluded for another. The difference is the diagnosis your prescriber is treating.

Route 1: the Medicare GLP-1 Bridge

The Bridge is a CMS demonstration running from July 1, 2026 through December 31, 2027. It covers all formulations of Wegovy, which means the single-dose pens, including the 7.2 mg pen, and the tablets.

What you pay. $50 per one-month supply, which for Wegovy is a box of four pens or a bottle of 30 tablets. The copay is the same at every dose. It doesn’t count toward your Part D deductible or out-of-pocket limit, Extra Help doesn’t reduce it, and no coupon can be applied to it.

Who qualifies. You must be 18 or older, enrolled in an eligible Part D plan, and prescribed Wegovy to reduce excess body weight alongside lifestyle modification. You must also meet a BMI tier, measured when you first started GLP-1 therapy: 35 or higher; 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a or above; or 27 or higher with pre-diabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease.

Who doesn’t. People with type 2 diabetes, moderate to severe obstructive sleep apnea or MASH, and anyone whose Part D plan has paid for a GLP-1 in 2026.

One prior authorization (the approval that lets the fill go through) from your prescriber covers refills and dose changes through December 31, 2027. That matters for Wegovy, because the label’s schedule steps the dose up over time. The Bridge explainer has every rule, and the eligibility checker runs through them for you.

Route 2: Part D for cardiovascular risk reduction

CMS names this use directly: Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. It’s coverable under the basic Part D benefit whether or not Wegovy is on your plan’s formulary (its list of covered drugs). Plans must follow their existing formulary exception processes for these requests.

There’s a rule here that catches people. If you’ve had a heart attack or stroke and have a BMI of 27 or higher, you might meet the Bridge criteria on paper. But CMS says that if the drug is being prescribed in order to reduce the risk of major adverse cardiovascular events, the prescription should go to the Part D plan, even if it’s also prescribed for weight. Your prescriber decides what the drug is being prescribed for, and the prior authorization asks them to attest to it.

The two routes cost differently. Under Part D, you pay according to your plan: a deductible of no more than $615 in 2026, then coinsurance, up to the $2,100 cap on out-of-pocket spending for covered Part D drugs. After that, you pay nothing for covered drugs for the rest of the year. Under the Bridge, you pay the flat copay each month and none of it counts toward that cap. Which is cheaper over a year depends on your plan and your other drugs. The Part D costs page compares them.

Already getting Wegovy through Part D?

Then you stay with Part D. CMS says anyone who has received a GLP-1 through their Part D plan in 2026 isn’t eligible for the Bridge and should keep getting the drug through the plan. That applies even if you’d otherwise meet every Bridge criterion.

The reverse also matters. If you’re approved for the Bridge and later fill a GLP-1 through your Part D plan, the Bridge approval stops working and the pharmacy gets a rejection on your next refill.

What changes in 2027

Semaglutide, the drug in Wegovy, Ozempic and Rybelsus, has a negotiated Medicare price that takes effect on January 1, 2027: $274 for a 30-day supply, which CMS sets against a 2024 list price of $959. For a package of four Wegovy 2.4 mg pens, the maximum fair price is $385.63. By law, Part D plans must include the selected drugs on their formularies.

This affects Wegovy filled through Part D for a covered use. It doesn’t lift the weight-loss exclusion, and the fact sheet doesn’t state what a beneficiary’s copay will be. For weight management, the Bridge remains the route through December 31, 2027. CMS hasn’t said what follows it.

If no Medicare route applies

If you don’t meet the Bridge criteria and have no Part D covered indication, Medicare won’t pay for Wegovy. The Wegovy savings offer isn’t open to you, because it excludes government beneficiaries.

That leaves paying cash. Novo Nordisk’s self-pay prices run from $149 a month for the lowest pill strength to $349 for the 2.4 mg pen, with no insurance used, no reimbursement, and eligibility terms that apply. Check those terms before you rely on a price, since the TrumpRx listing of the same Wegovy prices says government beneficiaries are excluded. The Wegovy cost page lists every price. If you also have Medicaid, its rules are separate and set state by state. See Medicaid coverage of GLP-1 medicines.

What to ask, and whom

  • Your prescriber: what is Wegovy being prescribed for, and what was my BMI when I started GLP-1 therapy? Those two answers decide the route.
  • Your pharmacy: for a weight-management prescription, ask them to send the claim to the Medicare GLP-1 Bridge. They don’t need a denial from your Part D plan first.
  • Your Part D plan: for a cardiovascular or MASH prescription, ask whether Wegovy is on the formulary, what tier it’s on, and how to request a formulary exception if it isn’t.
  • Medicare: if you’re not sure what type of plan you have, call 1-800-MEDICARE (1-800-633-4227).

Frequently asked questions

How much is Wegovy with Medicare?

Through the Medicare GLP-1 Bridge, it's $50 per one-month supply for the pen and $50 for the pill, if you meet the criteria. Through Part D for a covered use, the cost depends on your plan's deductible, tier and coinsurance, with out-of-pocket spending on covered Part D drugs capped at $2,100 in 2026.

Does Medicare cover the Wegovy pill?

Through the Bridge, yes. CMS says all formulations of Wegovy are available to eligible beneficiaries. That includes the tablets as well as the pens, at the same $50 copay per one-month supply. Your prescriber has to get a prior authorization, and the prescription must be for weight management.

Does Medicare cover Wegovy for heart disease?

Part D can. CMS names Wegovy to reduce the risk of major adverse cardiovascular events (such as heart attack and stroke) in adults with established cardiovascular disease and either obesity or overweight. It says this use is coverable under the basic Part D benefit, whether or not Wegovy is on your plan's formulary. Plans use their formulary exception process for these requests, so your prescriber may need to file one.

Will the 2027 negotiated price make Medicare cover Wegovy for weight loss?

No. CMS and Novo Nordisk agreed a negotiated price of $274 for a 30-day supply of semaglutide for 2027, and $385.63 for a package of four Wegovy 2.4 mg pens. That's a Part D price for Part D covered uses. It doesn't by itself make Wegovy covered for weight loss, which the Part D statute still excludes.

Can I use the Wegovy savings card with Medicare?

No. Novo Nordisk's Wegovy savings offer excludes government beneficiaries, which includes people on Medicare. CMS also says coupons and discount programs may not be applied to Bridge claims. If you don't qualify for the Bridge or a Part D covered use, ask your pharmacy about self-pay terms, and note that the TrumpRx Wegovy listing also excludes government beneficiaries.

Sources (12)

  1. 1.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  2. 2.
    CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
    “Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
  3. 3.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  4. 4.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  5. 5.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
  6. 6.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4524-14. Description of package: 2.4mg/0.75mL Pen, 4 Pens (Wegovy). MFP per package: $385.63.”
  7. 7.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “These negotiated prices will become effective on January 1, 2027. [...] As required by law, Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage-prescription drug plans, must include in their formularies the selected drugs for which CMS and the participating drug company have agreed to a negotiated price.”
  8. 8.
    Medicare.gov: How much does Medicare drug coverage cost?
    “After you reach your full deductible (if your plan has a deductible), you’ll pay 25% of the cost as coinsurance for your generic and brand-name drugs until your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027)(including certain payments made on your behalf, like through the Extra Help program). Then, you’ll automatically get “catastrophic coverage.” Catastrophic coverage stage: You won’t have to pay out-of-pocket for covered Part D drugs for the rest of the calendar year.”
  9. 9.
    Medicare.gov: How much does Medicare drug coverage cost?
    “No Medicare drug plan may have a deductible more than $615 in 2026 ($700 in 2027). Some Medicare drug plans don’t have a deductible.”
  10. 10.
  11. 11.
  12. 12.